Quentic Acquisition by AMCS Completed
5.7.2022 14:00:00 EEST | Business Wire | Press release
The German regulatory authorities have approved the sale of the Quentic GmbH to the AMCS Group. The transaction is hence closed and Quentic will be a part of AMCS as of July 2022.
AMCS, the leading global supplier of integrated software and vehicle technology for the environmental, utility, waste, recycling, and resource industries, and Quentic, one of the leading solution providers of Software as a Service for EHSQ and ESG management, announced the acquisition of Quentic by AMCS on May 12, 2022. As the regulatory authorities have now approved the transaction, the acquisition of the Berlin-based software provider for occupational safety, environmental, sustainability, and quality management took effect on June 30, 2022. "With this step, we open a new chapter in our 15-year company history," explains Markus Becker, CEO of Quentic. "The cooperation will further strengthen Quentic's growth of the past years. We particularly look forward to the professional collaboration and exchange in order to jointly provide the best digital business solutions for a healthier, cleaner and more sustainable future."
Technology portfolio for sustainable business processes
With the addition of Quentic to its portfolio, AMCS expands its offering of promising digital solutions that optimize workflows and have a direct positive impact on the environment. "Regardless of the industry, digitalization is a key enabler on the path to a global and sustainable circular economy," confirms Jimmy Martin CEO of AMCS. "With the variety of solutions in the AMCS portfolio, we aim to put these technologies at the fingertips of our customers. Integrated management of all processes related to occupational safety, environmental, sustainability and quality management, as offered by the Quentic SaaS platform and app, is therefore a valuable addition to our offering," Martin continues.
Becoming a market leader with sustainable growth
Markus Becker, Sebastian Mönnich and Hardy Menzel founded Quentic in 2007. Today, the company employs more than 250 people at 14 locations across Europe. More than 900 companies strengthen their processes in the areas of occupational safety, environmental, sustainability and quality management with Quentic software solutions. Business angels and financial investors supported the company’s growth in several rounds of financing. "We would like to thank our long-term partners One Peak, Morgan Stanley Expansion Capital and High-Tech Gründerfonds for the trustful and valuable cooperation. Together we have successfully put Quentic on the path to becoming the European market leader for EHSQ and ESG-management software and services. Now we are looking forward to continue on this path with AMCS," explains Markus Becker. The Quentic management team will continue to shape the company’s future together with the new owner AMCS.
About AMCS
AMCS is headquartered in Limerick, Ireland with offices in North America, Europe, and Australia employing over 1000 people across 18 countries. AMCS is a global leader of integrated software and vehicle technology for the environmental, recycling, and resource industries and offers optimization solutions to the broader transport and logistics market. AMCS helps over 4,000 customers globally to reduce their operating costs, increase asset utilization, optimize margins, and improve customer service. Their enterprise software and SaaS solutions deliver digital innovation to the emerging circular economy around the world.
About Quentic
Quentic is one of the leading solution providers of Software as a Service (SaaS) for EHSQ and ESG management. The Quentic platform comprises ten individually combinable modules and offers an ideal way for companies to manage Health & Safety, Risks & Audits, Incidents & Observations, Hazardous Chemicals, Control of Work, Legal Compliance, Online Instructions, Processes, Environmental Management and Sustainability.
The company is headquartered in Berlin, Germany, and employs more than 250 people. Branch offices are located in Germany, Austria, Switzerland, Finland, Sweden, Denmark, Belgium, the Netherlands, France, Spain and Italy.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005137/en/
Contact information
Mark Abbas
pr@amcsgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom